Hepatocellular Carcinoma Trial Landscape (November 2026)

Last updated: Nov 19, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

671
Recruiting
149
Phase 1
325
Phase 2
63
Phase 3
23
Phase 4

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Looking for hepatocellular carcinoma trials matched to your specific case?

Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.

Find My Matches →

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

Checkpoint inhibitor
156
Other / unclassified
56
Bispecific antibody
47
Tyrosine kinase inhibitor (TKI)
33
Monoclonal antibody
22
Chemotherapy
22
CAR-T cellular therapy
22
Other inhibitor
11
Vaccine (other)
10
Antibody-drug conjugate (ADC)
10
Small-molecule inhibitor
8
TIL cellular therapy
4

Recently Updated Trials

NCTPhaseTitleMechanism
NCT066003211A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaBCAT mRNA -- RNA interference (siRNA)
NCT078848772PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancerUnknown mechanism
NCT058421741, 2Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular CarcinomaAutophagy inhibition + chemotherapy -- hydroxychloroquine plus lipiodol
NCT05727787—vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCCUnknown mechanism
NCT050038951GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesGPC3 -- chimeric antigen receptor T cell therapy (CAR-T)

Top Sponsors

SponsorRecruiting trials
Sun Yat-sen University33
Tianjin Medical University Cancer Institute and Hospital19
Tongji Hospital15
Second Affiliated Hospital of Guangzhou Medical University15
Fudan University14

Geographic Distribution

Countries/regions with the most active trial sites for hepatocellular carcinoma. A multi-site trial is counted once per country/region.

China
320
United States
122
France
39
South Korea
32
Taiwan
30
Italy
19
Germany
17
Canada
16
Spain
14
Australia
12

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

StartNCTTitleMechanism
Dec 1, 2026NCT07878689Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular CarcinomaWnt pathway -- protein-protein interaction inhibitor (small molecule)
Nov 2026NCT07861425Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIsGlypican-3 (GPC-3) -- dual-payload antibody-drug conjugate (ADC)
Nov 2026NCT07899632A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid TumorsSTAT3 -- targeted protein degradation (degrader)
Oct 28, 2026NCT07430202A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)DNAJB1-PRKACA fusion kinase -- peptide vaccine plus glutamine antagonist plus PD-1 and CTLA-4 immune checkpoint inhibitors
Oct 7, 2026NCT07627191GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular CancerGLP-1 receptor -- receptor agonist (GLP-1 RA)
Oct 1, 2026NCT07835737Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular CarcinomaPD-L1 + VEGF -- bispecific antibody (Atezolizumab and Bevacizumab); Folic Acid -- metabolic supplement
Sep 30, 2026NCT07761286Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaVEGF -- monoclonal antibody (Bevacizumab); PD-1 -- immune checkpoint inhibitor (Sintilimab); Unknown target -- SYS6090 and SYS6043 mechanism unclear
Sep 1, 2026NCT07446257THIO and Cadonilimab in Resectable Hepatocellular CarcinomaPD-1 + CTLA-4 + nucleoside analog -- immune checkpoint inhibitor plus nucleoside analog

You've seen the hepatocellular carcinoma landscape. Now find the trials that fit your case.

Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.

Find My Matches →

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.